Smith & Nephew plc (SNN)
Healthcare › Orthopedic, Prosthetic & Surgical Appliances & Supplies
Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- Trading 225% above Graham Number — above intrinsic value estimate
- Piotroski F-Score 6/9 — moderate financial health
- ROE of 11.8% — below-average profitability
- Revenue growing at 6% annually
Smith & Nephew plc (SNN) is a Healthcare company operating in Orthopedic, Prosthetic & Surgical Appliances & Supplies, listed on the NYSE , with a market capitalisation of $28.0 billion . Key value metrics: P/E ratio 44.9, P/B ratio 5.30, Piotroski F-Score 6 out of 9 (moderate financial health) .
Value Score
Key Metrics
Smith & Nephew plc — Fundamental Analysis Summary
Smith & Nephew plc (SNN) is currently trading 225% above its Graham Number of $9.83, suggesting the market price exceeds Benjamin Graham's intrinsic value estimate. The stock carries an elevated trailing P/E ratio of 44.9x.
On financial health, SNN shows a moderate Piotroski F-Score of 6/9, and modest return on equity of 11.8% (sector average: -19.8%), and manageable leverage with a debt-to-equity ratio of 0.59.
StockPik's composite Value Score for SNN is 53/100 — an above-average value rating. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
SNN reports a high gross margin of 68.0% (sector average: 33.5%) and a solid operating margin of 12.9%.
SNN shows revenue growing at 6% year-over-year, with earnings growing at 52%.